Adolescence is a unique period of development characterized by enhanced tobacco use and long-term vulnerability to neurochemical changes produced by adolescent nicotine exposure. In order to understand the underlying mechanisms that contribute to developmental differences in tobacco use, this study compared changes in cholinergic transmission during nicotine exposure and withdrawal in naïve adult rats compared to (1) adolescent rats and (2) adult rats that were pre-exposed to nicotine during adolescence. The first study compared extracellular levels of acetylcholine (ACh) in the nucleus accumbens (NAc) during nicotine exposure and precipitated withdrawal using microdialysis procedures. Adolescent (postnatal day, PND, 28-42) and adult rats (PND60-74) were prepared with osmotic pumps that delivered nicotine for 14 days (adolescents 4.7 mg/kg/day; adults 3.2 mg/kg/day; expressed as base). Another group of adults was exposed to nicotine during adolescence and then again in adulthood (pre-exposed adults) using similar methods. Control rats received a sham surgery. Following 13 days of nicotine exposure, the rats were implanted with microdialysis probes in the NAc. The following day, dialysis samples were collected during baseline and following systemic administration of the nicotinic receptor antagonist mecamylamine (1.5 and 3.0 mg/kg, i.p.) to precipitate withdrawal. A second study compared various metabolic differences in cholinergic transmission using the same treatment procedures as the first study. Following 14 days of nicotine exposure, the NAc was dissected and acetylcholinesterase (AChE) activity was compared across groups. In order to examine potential group differences in nicotine metabolism, blood plasma levels of cotinine (a nicotine metabolite) were also compared following 14 days of nicotine exposure. The results from the first study revealed that nicotine exposure increased baseline ACh levels to a greater extent in adolescent versus adult rats. During nicotine withdrawal, ACh levels in the NAc were increased in a similar manner in adolescent versus adult rats. However, the increase in ACh that was observed in adult rats experiencing nicotine withdrawal was blunted in pre-exposed adults. These neurochemical effects do not appear to be related to nicotine metabolism, as plasma cotinine levels were similar across all groups. The second study revealed that nicotine exposure increased AChE activity in the NAc to a greater extent in adolescent versus adult rats. There was no difference in AChE activity in pre-exposed versus naïve adult rats. In conclusion, our results suggest that nicotine exposure during adolescence enhances baseline ACh in the NAc. However, the finding that ACh levels were similar during withdrawal in adolescent and adult rats suggests that the enhanced vulnerability to tobacco use during adolescence is not related to age differences in withdrawal-induced increases in cholinergic transmission. Our results also suggest that exposure to nicotine during adolescence suppresses withdrawal-induced increases in cholinergic responses during withdrawal. Taken together, this report illustrates important short- and long-term changes within cholinergic systems that may contribute to the enhanced susceptibility to tobacco use during adolescence.

1.
Dani JA, Jenson D, Broussard JI, De Biasi M: Neurophysiology of nicotine addiction. J Addict Res Ther 2011;20:S1.
2.
O'Dell LE, Bruijnzeel AW, Smith RT, Parsons LH, Merves ML, Goldberger BA, Koob GF, Markou A: Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology 2006;186:612-619.
3.
Shram MJ, Siu EC, Li Z, Tyndale RF, Lê AD: Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology 2008;198:181-190.
4.
Kota D, Martin BR, Robinson SE, Damaj MI: Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther 2007;322:399-407.
5.
O'Dell LE, Torres OV, Natividad LA, Tejeda HA: Adolescent nicotine exposure produces less affective measures of withdrawal relative to adult nicotine exposure in male rats. Neurotoxicol Teratol 2007;29:17-22.
6.
Carboni E, Bortone L, Giua C, Di Chiara G: Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend 2000;58:93-102.
7.
Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH: Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 1998;779:214-225.
8.
Rada P, Jensen K, Hoebel BG: Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology 2001;157:105-110.
9.
Natividad LA, Tejeda HA, Torres OV, O'Dell LE: Nicotine withdrawal produces a decrease in extracellular levels of dopamine in the nucleus accumbens that is lower in adolescent versus adult male rats. Synapse 2010;64:136-145.
10.
Tejeda HA, Natividad LA, Orfila JE, Torres OV, O'Dell LE: Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology 2012;224:289-301.
11.
Natividad LA, Parsons LH, OV, O'Dell LE: Adolescent rats are resistant to adaptations in excitatory and inhibitory mechanisms that modulate mesolimbic dopamine during nicotine withdrawal. J Neurochem 2012;123:578-588.
12.
Rada P, Johnson DF, Lewis MJ, Hoebel BG: In alcohol-treated rats, naloxone decreases extracellular dopamine and increases acetylcholine in the nucleus accumbens: evidence of opioid withdrawal. Pharmacol Biochem Behav 2004;79:599-605.
13.
Rossetti ZL, Hmaidan Y, Gessa GL: Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 1992;221:227-234.
14.
Mark GP, Weinberg JB, Rada PV, Hoebel BG: Extracellular acetylcholine is increased in the nucleus accumbens following the presentation of an aversively conditioned taste stimulus. Brain Res 1995;688:184-188.
15.
Trauth JA, Seidler FJ, Slotkin TA: An animal model of adolescent nicotine exposure: effects on gene expression and macromolecular constituents in rat brain regions. Brain Res 2000;867:29-39.
16.
Damsma G, Westerink BHC: A microdialysis and automated on-line analysis approach to study central cholinergic transmission in vivo; in Robinson TE, Justice JB (eds): Microdialysis in the Neurosciences. New York, Elsevier, 1991, pp 237-252.
17.
Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
18.
Penton RE, Lester RA: Cellular events in nicotine addiction. Semin Cell Dev Biol 2009;20:418-431.
19.
Crespo JA, Stockl P, Zorn K, Saria A, Zernig G: Nucleus accumbens core acetylcholine is preferentially activated during acquisition of drug- vs food-reinforced behavior. Neuropsychopharmacology 2008;33:3213-3220.
20.
Rada P, Johnson DF, Lewis MJ, Hoebel BG: In alcohol-treated rats, naloxone decreases extracellular dopamine and increases acetylcholine in the nucleus accumbens: evidence of opioid withdrawal. Pharmacol Biochem Behav 2004;79:599-605.
21.
Rossetti ZL, Hmaidan Y, Gessa GL: Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 1992;221:227-234.
22.
Mark GP, Weinberg JB, Rada PV, Hoebel BG: Extracellular acetylcholine is increased in the nucleus accumbens following the presentation of an aversively conditioned taste stimulus. Brain Res 1995;688:184-188.
23.
Adriani W, Laviola G: Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. Behav Pharmacol 2004;15:341-352.
24.
Barron S, White A, Swartzwelder HS, Bell RL, Rodd ZA, Slawecki CJ, Ehlers CL, Levin ED, Rezvani AH, Spear LP: Adolescent vulnerabilities to chronic alcohol or nicotine exposure: findings from rodent models. Alcohol Clin Exp Res 2005;29:1720-1725.
25.
O'Dell LE: A psychobiological framework of the substrates that mediate nicotine use during adolescence. Neuropharmacology 2009;56:263-278.
26.
Collins SL, Wade D, Ledon J, Izenwasser S: Neurochemical alterations produced by daily nicotine exposure in periadolescent vs adult male rats. Eur J Pharmacol 2004;502:75-85.
27.
Counotte DS, Goriounova NA, Moretti M, Smoluch MT, Irth H, Clementi F, Schoffelmeer AN, Mansvelder HD, Smit AB, Gotti C, Spijker S: Adolescent nicotine exposure transiently increases high-affinity nicotinic receptors and modulates inhibitory synaptic transmission in rat medial prefrontal cortex. FASEB J 2012;26:1810-1820.
28.
Doura MB, Gold AB, Keller AB, Perry DC: Adult and periadolescent rats differ in expression of nicotinic cholinergic receptor subtypes and in the response of these subtypes to chronic nicotine exposure. Brain Res 2008;1215:40-52.
29.
Trauth JA, Seidler FJ, McCook EC, Slotkin TA: Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. Brain Res 1999;851:9-19.
30.
Winzer-Serhan UH: Long-term consequences of maternal smoking and developmental chronic nicotine exposure. Front Biosci 2008;13:636-649.
31.
Adriani W, Deroche-Gamonet V, Le Moal M, Laviola G, Piazza PV: Pre-exposure during or following adolescence differently affects nicotine-rewarding properties in adult rats. Psychopharmacology 2006;184:382-390.
32.
Levin ED, Rezvani A, Montoya R, Rose J, Swartrzwelder H: Adolescent-onset nicotine self-administration modeled in female rats. Psychopharmacology 2003;169:141-149.
33.
Natividad LA, Torres OV, Friedman TC, O'Dell LE: Adolescence is a period of development characterized by short- and long-term vulnerability to the rewarding effects of nicotine and reduced sensitivity to the anorectic effects of this drug. Behav Brain Res 2013;257:275-285.
34.
Smith LN, McDonald CG, Bergstrom HC, Brielmaier JM, Eppolito AK, Wheeler TL, Falco AM, Smith RF: Long-term changes in fear conditioning and anxiety-like behavior following nicotine exposure in adult versus adolescent rats. Pharmacol Biochem Behav 2006;85:91-97.
35.
Cruz FC, Delucia R, Planeta CS: Differential behavioral and neuroendocrine effects of repeated nicotine in adolescent and adult rats. Pharmacol Biochem Behav 2005;80:411-417.
36.
Kane VB, Fu Y, Matta SG, Sharp BM: Gestational nicotine exposure attenuates nicotine-stimulated dopamine release in the nucleus accumbens shell of adolescent Lewis rats. J Pharmacol Exp Ther 2004;308:521-528.
37.
Trauth JA, Seidler FJ, Ali SF, Slotkin TA: Adolescent nicotine exposure produces immediate and long-term changes in CNS noradrenergic and dopaminergic function. Brain Res 2001;892:269-280.
38.
Ginzel KH, Maritz GS, Marks DF, Neuberger M, Pauly JR, Polito JR, Schulte-Hermann R, Slotkin TA: Critical review: nicotine for the fetus, the infant and the adolescent? J Health Psychol 2007;12:215-224.
39.
Slotkin TA, Bodwell BE, Ryde IT, Seidler FJ: Adolescent nicotine treatment changes the response of acetylcholine systems to subsequent nicotine administration in adulthood. Brain Res Bull 2008;76:152-165.
40.
Hanson KA, Allenn S, Jensen S, Hatsukami D: Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res 2003;5:515-526.
41.
Hurt RD, Croghan GA, Beede SD, Wolter TD, Croghan IT, Patten CA: Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med 2000;154:31-37.
42.
Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, Schroeder JR: Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005;115:407-414.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.